For research use only. Not for therapeutic Use.
PGP-4008 is a specific P-glycoprotein (Pgp) inhibitor. PGP-4008 inhibits tumor growth in a murine syngeneic Pgp-mediated multiple agent resistance (MDR) solid tumor model when given in combination with Doxorubicin[1].
| Catalog Number | I008722 |
| CAS Number | 365565-02-2 |
| Synonyms | N-(1-benzyl-2,3-dihydropyrrolo[2,3-b]quinolin-4-yl)-2-phenylacetamide |
| Molecular Formula | C26H23N3O |
| Purity | ≥95% |
| InChI | InChI=1S/C26H23N3O/c30-24(17-19-9-3-1-4-10-19)28-25-21-13-7-8-14-23(21)27-26-22(25)15-16-29(26)18-20-11-5-2-6-12-20/h1-14H,15-18H2,(H,27,28,30) |
| InChIKey | HVIAKQBMYMKWII-UHFFFAOYSA-N |
| SMILES | C1CN(C2=NC3=CC=CC=C3C(=C21)NC(=O)CC4=CC=CC=C4)CC5=CC=CC=C5 |
| Reference | [1]. Brian D Lee, et al. Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein. J Med Chem. 2004 Mar 11;47(6):1413-22. |
